Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Thiogenesis Therapeutics Corp TTIPF


Primary Symbol: V.TTI

Healthcare Biotechnology
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:TTI)

Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease

Newsfile December 10, 2024

Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates

Newsfile November 28, 2024

Thiogenesis Announces Important Core Patent Allowed in Europe

Newsfile November 4, 2024

Thiogenesis Announces Investor Relations Engagement

Newsfile September 27, 2024

Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium

Newsfile September 17, 2024

Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program

Newsfile August 20, 2024

Thiogenesis Announces Leigh Syndrome Clinical Program

Newsfile July 18, 2024

Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS

Newsfile March 25, 2024

Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement

Newsfile December 20, 2023
View More News ››

Opinion & Analysis (TSXV:TTI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:TTI)

Unlocking Rare Disease Potential

Unlocking Rare Disease Potential: Why Thiogenesis Therapeutics (TTI.v) Could Be a Game-Changer Interested in a unique opportunity in...
MarketMakerss - 5 days ago

TTI Advances Lead Drug Targeting Pediatric & Orphan Diseases

A mid-December financial analysis from Valuation Lab highlights the significant potential of Thiogenesis Therapeutics' (Ticker: TTI...
1StockInformer - 5 days ago

Informative Post on Thiogenesis

Recommend this post on Thiogenesis Therapeutics Corp. (TTI.v TTIPF) and the development of the drug TTI-0102 which is designed to treat...
SkywalkerofLuke - 7 days ago

TTI Targets Multi-Billion Dollar Markets, Advancing Trials

Thiogenesis Therapeutics Corp. (Ticker: TTI.v) is a clinical-stage biopharmaceutical company focused on developing thiol-active...
1StockInformer - 7 days ago

Groundbreaking BioChem Opportunity

Offering a groundbreaking investment opportunity with a projected upside of 1130%, Thiogenesis Therapeutics (TTI.v) is driven by its...
MarketMakerss - 12 days ago

Good Recap on Thiogenesis

Good recap of Thiogenesis Therapeutics Corp. (TTI.v TTIPF) and the development of the drug TTI-0102 which is designed to treat...
SkywalkerofLuke - 13 days ago
View more Bullboard ››

AKITA Drilling Ltd

AKITA Drilling Ltd

AKITA Drilling Ltd. provides contract drilling services, primarily to the oil and gas industry, in Canada and the United ...
View More »